PHAR
Pharming Group NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$889.88M
P/E Ratio
66.32
EPS
$0.19
Beta
0.12
52W High
$21.34
52W Low
$9.54
50-Day MA
$15.60
200-Day MA
$15.69
Dividend Yield
—
Profit Margin
3.34%
Forward P/E
26.45
PEG Ratio
—
About Pharming Group NV
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Fundamentals
| Revenue (TTM) | $369.49M |
| Gross Profit (TTM) | $325.67M |
| EBITDA | $42.28M |
| Operating Margin | -6.78% |
| Return on Equity | 5.04% |
| Return on Assets | 4.89% |
| Revenue/Share (TTM) | $5.22 |
| Book Value | $3.61 |
| Price-to-Book | 3.31 |
| Price-to-Sales (TTM) | 2.41 |
| EV/Revenue | 2.337 |
| EV/EBITDA | 21.61 |
| Quarterly Earnings Growth (YoY) | 104.20% |
| Quarterly Revenue Growth (YoY) | -8.40% |
| Shares Outstanding | $70.63M |
| Float | $733.15M |
| % Insiders | 0.00% |
| % Institutions | 0.17% |
Historical Volatility
HV 10-Day
30.84%
HV 20-Day
119.06%
HV 30-Day
98.56%
HV 60-Day
76.99%
HV Rank
96.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($34.35 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026